Key Insights

Highlights

Treatment Research

2 treatments under study, led by Allogeneic Cart

Related Conditions

Often studied with 5 related conditions

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

50.0%

1 terminated out of 2 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

0

Data Visualizations

Phase Distribution

2Total
Phase 1 (2)

Trial Status

Not Yet Recruiting1
Terminated1

Clinical Trials (2)

Showing 2 of 2 trials
NCT04865458Phase 1TerminatedPrimary

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics of HEC89736 in Patients With Relapsed or Refractory B-cell Hematologic Malignancies

NCT07113496Phase 1Not Yet RecruitingPrimary

RN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies

Showing all 2 trials

Research Network

Common Treatments

  • Allogeneic Cart1
  • Hec897361

Active Sponsors

  • The First Affiliated Hospital with Nanjing Medical University1
  • Sunshine Lake Pharma Co., Ltd.1

Top Investigators

Related Conditions

  • Mature Bcell Lymphoma1
  • Bcell Acute Lymphoblastic Leukemia Ball1
  • Multiple Myeloma Mm1
  • Plasmablastic Lymphoma1
  • Relapsed Or Refractory Cd19bcma Hematologic Malignancies1

Activity Timeline